Osorio-Toro Luis Miguel, Bonilla-Bonilla Diana Marcela, Escobar-Dávila Santiago Leandro, Quintana-Ospina Jhon Herney, Melo-Burbano Luis Álvaro, Benitez-Escobar Edith Norela, Galindes-Casanova Duván Arley, Daza-Arana Jorge Enrique, Rivas-Tafurt Giovanna Patricia
Specialization Program in Internal Medicine, School of Health, Universidad Santiago de Cali, Santiago de Cali, Colombia.
Research and Education Department, Clínica de Occidente S.A., Santiago de Cali, Colombia.
Case Rep Oncol. 2023 Aug 14;16(1):613-620. doi: 10.1159/000531389. eCollection 2023 Jan-Dec.
We present the case of a 64-year-old female with stage IV gastric adenocarcinoma, pulmonary, and abdominal wall metastases, and no history of cardiovascular disease. In palliative care, she received systemic cytotoxic treatment with fluorouracil, leucovorin, oxaliplatin, and docetaxel protocol, which was well tolerated over five cycles. During cycle 6, she presented with cardiovascular symptoms with hemodynamic consequences while receiving oxaliplatin injection without docetaxel or 5-fluorouracil. She was transferred to the emergency department and then to the intensive care unit. She developed no complications during the hospital stay and was discharged after 10 days with preserved systolic function and no structural changes at the myocardial level. The electrocardiogram, echocardiogram, cardiac catheterization, and magnetic resonance imaging findings indicated an oxaliplatin-associated Takotsubo syndrome. The immunochemistry analysis showed PD-L1 expression level TPS: 40% and the foundation one genomic profiling revealed high mutation load, microsatellite instability, and HER2 not found. The patient is currently asymptomatic and on pembrolizumab monotherapy with good tolerance and partial treatment response.
我们报告了一例64岁女性,患有IV期胃腺癌,伴有肺和腹壁转移,且无心血管疾病史。在姑息治疗中,她接受了氟尿嘧啶、亚叶酸钙、奥沙利铂和多西他赛方案的全身细胞毒性治疗,五个周期均耐受良好。在第6周期,她在接受奥沙利铂注射(未使用多西他赛或5-氟尿嘧啶)时出现了心血管症状并伴有血流动力学后果。她被转至急诊科,随后转入重症监护病房。住院期间未出现并发症,10天后出院,收缩功能保留,心肌层面无结构改变。心电图、超声心动图、心脏导管检查和磁共振成像结果提示为奥沙利铂相关的应激性心肌病。免疫化学分析显示PD-L1表达水平TPS:40%,FoundationOne基因组分析显示高突变负荷、微卫星不稳定性,未发现HER2。该患者目前无症状,正在接受帕博利珠单抗单药治疗,耐受性良好且有部分治疗反应。